Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -2.91
- Piotroski Score 7.00
- Grade Buy
- Symbol (KPRX)
- Company Kiora Pharmaceuticals, Inc.
- Price $3.31
- Changes Percentage (-4.06%)
- Change -$0.14
- Day Low $3.31
- Day High $3.41
- Year High $8.98
Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1 clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases. The company is also developing KIO-101, an eye drop that is in Phase 2 clinical trial for the treatment of ocular presentation of rheumatoid arthritis, as well as for treating non-infectious posterior uveitis; and KIO-201, an eye drop, which is in Phase 3 clinical trial for treating patients undergoing PRK surgery for corneal wound repair after refractive surgery. The company was formerly known as Eyegate Pharmaceuticals, Inc. and changed its name to Kiora Pharmaceuticals, Inc. in November 2021. Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Salt Lake City, Utah.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 02/28/2025
- Fiscal Year End N/A
- Average Stock Price Target $0.00
- High Stock Price Target $0.00
- Low Stock Price Target $0.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$1.31
- Trailing P/E Ratio -0.36
- Forward P/E Ratio -0.36
- P/E Growth -0.36
- Net Income $-12,513,896
Income Statement
Quarterly
Annual
Latest News of KPRX
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) stock most popular amongst retail investors who own 39%, while hedge funds hold 31%
Ownership data and analyst forecasts provide valuable insights into a company's potential. Retail investors hold 39% of Kiora Pharmaceuticals, with hedge funds at 31%. Institutional ownership, insider...
By Yahoo! Finance | 5 months ago
